

# GE HealthCare Technologies Inc. (GEHC)

Nasdaq; healthcare; SIC 3844, X-Ray Apparatus & Tubes & Related Irradiation Apparatus; CIK 0001932393

GE Healthcare Technologies Inc.

GEHC; healthcare

Grade

B

A

B

C

D

E

second fifth of 371 graded peers  
percentile 26.2; sampling error 2.5 points; lower is stronger

Rank

98 of 371

Profitability

C/D

percentile 59.2

Solvency

C

percentile 43.0

Growth and financing

A

percentile 16.0

Reliability

0.94 AUC

filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025

Peer failure rate

0.52% a year

Item 1.03 bankruptcies, same asset band, 2012 to 2025

Size band

over \$2.67B assets

total assets \$36.9B

Standard universe

inside

revenue above \$1M and assets above \$10M

Warnings

none active

not computable: distress

Inputs computable

9 of 14

Graded from

filings received through Feb 4, 2026

247 days before the rescans; latest periodic filing 10-Q received Jul 29, 2026

Last close

\$64.23

2026-10-08; market equity \$29.2B

Price used in grade

None




B, the elk

second fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans

split-adjusted close; the letter is fixed at the rescans that set it



| Date | Price (\$) | Label |
|------|------------|-------|
| Nov  | ~75        | B/C   |
| Jan  | ~85        |       |
| Mar  | ~80        | C     |
| May  | ~60        |       |
| Jul  | ~70        |       |
| Sep  | ~75        | B     |

Rescans on file: B/C from Feb 21, 2025, C from Mar 21, 2025, B from Feb 21, 2026

**Letter at every rescan**

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



## Business, in the company's words

opening of Item 1 of the 10-K received Feb 4, 2026

GE HealthCare Technologies Inc. ("GE HealthCare," the "Company," "our," "us," or "we") is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. We have approximately 54,000 colleagues dedicated to our purpose to create a world where healthcare has no limits. Serving patients and providers for nearly 130 years, GE HealthCare is delivering bold innovations designed

for the next era of medicine to help clinicians deliver more personalized, precise patient care.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

| Input                                        | Percentile, 0 to 100   | Value          | Peer median | Percentile | Peers | Period end                                                                                 |
|----------------------------------------------|------------------------|----------------|-------------|------------|-------|--------------------------------------------------------------------------------------------|
| Profitability, sleeve percentile 59.2        |                        |                |             |            |       |                                                                                            |
| Gross profitability                          | <div><div></div></div> | 22.3%          | 32.2%       | 60.4       | 372   | 2025-12-31                                                                                 |
| Return on invested capital                   | <div><div></div></div> | 14.1%          | 9.3%        | 35.6       | 74    | 2025-12-31                                                                                 |
| Accruals ratio                               | <div><div></div></div> | 0.3%           | (6.6%)      | 81.6       | 811   | 2025-12-31                                                                                 |
| Gross margin stability, five years           |                        | not computable | 2.8 pts     |            |       | five annual gross margins are required; found 3                                            |
| Solvency, sleeve percentile 43.0             |                        |                |             |            |       |                                                                                            |
| Twelve-month failure probability             |                        | not computable | 0.07%       |            |       | latest liabilities, cash plus short-term investments, book equity, and shares are required |
| Altman Z double-prime                        | <div><div></div></div> | 1.99           | (0.31)      | 28.9       | 756   | 2025-12-31                                                                                 |
| Net debt to EBITDA                           | <div><div></div></div> | 1.81x          | 1.82x       | 50.0       | 75    | 2025-12-31                                                                                 |
| Interest coverage                            | <div><div></div></div> | 6.28x          | (4.51x)     | 10.0       | 81    | 2025-12-31                                                                                 |
| Current ratio                                | <div><div></div></div> | 1.37x          | 2.96x       | 83.1       | 839   | 2025-12-31                                                                                 |
| Growth and financing, sleeve percentile 16.0 |                        |                |             |            |       |                                                                                            |
| Revenue growth, three-year compound          |                        | not computable | 10.0%       |            |       | four annual observations are required; found 3                                             |
| Free cash flow growth, three-year compound   |                        | not computable | 10.9%       |            |       | four consecutive annual FCF observations are required; found 3                             |
| Reinvestment rate                            | <div><div></div></div> | 150.8%         | 37.1%       | 21.4       | 104   | 2025-12-31                                                                                 |
| Asset growth, three years                    |                        | not computable | 2.1%        |            |       | four annual observations are required; found 3                                             |
| Net share issuance, one year                 | <div><div></div></div> | (0.3%)         | 2.5%        | 10.6       | 634   | 2026-01-28                                                                                 |

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

| Rank | Company                                  | Percentile | Letter | Warnings                                 |
|------|------------------------------------------|------------|--------|------------------------------------------|
| 93   | Mannatech Inc. (MTEX)                    | 24.9       | B      | late filer,<br>fortress<br>balance sheet |
| 94   | NeuroPace Inc. (NPCE)                    | 25.1       | B      |                                          |
| 95   | Zoetis Inc. (ZTS)                        | 25.4       | B      |                                          |
| 96   | Mirum Pharmaceuticals, Inc. (MIRM)       | 25.7       | B      |                                          |
| 97   | Phibro Animal Health Corp. (PAHC)        | 25.9       | B      |                                          |
| 98   | GE HealthCare Technologies Inc. (GEHC) < | 26.2       | B      |                                          |
| 99   | Sensus Healthcare, Inc. (SRTS)           | 26.5       | B      |                                          |
| 100  | Lineage Cell Therapeutics, Inc. (LCTX)   | 26.8       | B      |                                          |
| 101  | Traverse Therapeutics, Inc. (TVTX)       | 27.0       | B      |                                          |
| 102  | Tela Bio, Inc. (TELA)                    | 27.3       | B      | fortress<br>balance sheet                |
| 103  | Alphatec Holdings, Inc. (ATEC)           | 27.6       | B      |                                          |

## What the price implies

at the 2026-10-08 close; none enters the grade

| Measure                                                 | Value          | Peer median | Percentile |
|---------------------------------------------------------|----------------|-------------|------------|
| Twelve-month price change, skipping the latest month    | (5.0%)         | 8.0%        | 43         |
| Distance from 52-week high                              | (27.2%)        | (31.4%)     | 56         |
| EBIT to enterprise value                                | 7.5%           | (1.5%)      | 86         |
| Free cash flow yield                                    | 5.2%           | (1.0%)      | 82         |
| Book value to price                                     | 0.37           | 0.28        | 58         |
| Sales to price                                          | 0.71           | 0.31        | 76         |
| Composite equity issuance, five years                   | not computable | 20.3%       |            |
| Relative strength against the sector, log excess return | (0.26)         | (0.14)      | 43         |

## Diagnostics

not in the grade

| Measure                                                | Value                           |
|--------------------------------------------------------|---------------------------------|
| <b>Piotroski F-score 6 of 9, period end 2025-12-31</b> |                                 |
| Return on assets above zero                            | pass                            |
| Operating cash flow above zero                         | pass                            |
| Return on assets improved                              | pass                            |
| Operating cash flow exceeds net income                 | fail                            |
| Long-term leverage fell                                | fail                            |
| Current ratio improved                                 | pass                            |
| No new shares issued                                   | pass                            |
| Gross margin improved                                  | fail                            |
| Asset turnover improved                                | pass                            |
| <b>Cash, filings, liquidity</b>                        |                                 |
| Cash and equivalents                                   | \$2.3B                          |
| Operating cash flow, four quarters                     | \$2.0B                          |
| Months of runway                                       | not finite                      |
| Days since last periodic filing                        | 72 (10-Q received Jul 29, 2026) |
| Median daily dollar volume, 63 sessions                | \$228.4M                        |

## Sources

each row links to the filing index on sec.gov

| # | Concept          | XBRL tag                                                            | Value    | Period end | Received   | Form | Accession            |
|---|------------------|---------------------------------------------------------------------|----------|------------|------------|------|----------------------|
| 1 | gross profit     | us-gaap:GrossProfit                                                 | \$8.2B   | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 2 | assets           | us-gaap:Assets                                                      | \$36.9B  | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 3 | operating income | us-gaap:OperatingIncomeLoss                                         | \$2.8B   | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 4 | pretax income    | us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord | \$2.8B   | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 5 | income tax       | us-gaap:IncomeTaxExpenseBenefit                                     | \$614.0M | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |

|    |                           |                                                                       |             |            |            |      |                      |
|----|---------------------------|-----------------------------------------------------------------------|-------------|------------|------------|------|----------------------|
| 6  | total debt                | us-gaap:LongTermDebt                                                  | \$10.0B     | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 7  | book equity               | us-gaap:StockholdersEquity                                            | \$10.4B     | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 8  | cash                      | us-gaap:CashAndCashEquivalentsAtCarryingValue                         | \$4.5B      | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 9  | total debt                | us-gaap:LongTermDebt                                                  | \$9.0B      | 2024-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 10 | book equity               | us-gaap:StockholdersEquity                                            | \$8.4B      | 2024-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 11 | cash                      | us-gaap:CashAndCashEquivalentsAtCarryingValue                         | \$2.9B      | 2024-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 12 | net income                | us-gaap:NetIncomeLoss                                                 | \$2.1B      | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 13 | operating cash flow       | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperation | \$2.0B      | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 14 | assets                    | us-gaap:Assets                                                        | \$33.1B     | 2024-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 15 | current assets            | us-gaap:AssetsCurrent                                                 | \$12.5B     | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 16 | current liabilities       | us-gaap:LiabilitiesCurrent                                            | \$9.1B      | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 17 | retained earnings         | us-gaap:RetainedEarningsAccumulatedDeficit                            | \$5.3B      | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 18 | liabilities               | us-gaap:Liabilities                                                   | \$26.3B     | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 19 | depreciation amortization | us-gaap:Depreciation                                                  | \$287.0M    | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 20 | interest expense          | us-gaap:InterestAndDebtExpense                                        | \$440.0M    | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 21 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax           | \$20.6B     | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 22 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax           | \$19.7B     | 2024-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 23 | revenue                   | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax           | \$19.6B     | 2023-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 24 | capital expenditure       | us-gaap:PaymentsToAcquireProductiveAssets                             | \$482.0M    | 2025-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 25 | current assets            | us-gaap:AssetsCurrent                                                 | \$9.9B      | 2024-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 26 | current liabilities       | us-gaap:LiabilitiesCurrent                                            | \$9.6B      | 2024-12-31 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 27 | assets                    | us-gaap:Assets                                                        | \$32.5B     | 2023-12-31 | 2025-02-13 | 10-K | 0001932393-25-000005 |
| 28 | shares outstanding        | dei:EntityCommonStockSharesOutstanding                                | 455,749,767 | 2026-01-28 | 2026-02-04 | 10-K | 0001932393-26-000007 |
| 29 | shares outstanding        | dei:EntityCommonStockSharesOutstanding                                | 457,298,310 | 2025-02-06 | 2025-02-13 | 10-K | 0001932393-25-000005 |